EA200900691A1 - Применение ингибиторов iap для лечения острого миелоидного лейкоза - Google Patents

Применение ингибиторов iap для лечения острого миелоидного лейкоза

Info

Publication number
EA200900691A1
EA200900691A1 EA200900691A EA200900691A EA200900691A1 EA 200900691 A1 EA200900691 A1 EA 200900691A1 EA 200900691 A EA200900691 A EA 200900691A EA 200900691 A EA200900691 A EA 200900691A EA 200900691 A1 EA200900691 A1 EA 200900691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
treatment
myeloid leukemia
acute myeloid
iap
Prior art date
Application number
EA200900691A
Other languages
English (en)
Inventor
Ли Зауэл
Яо Яо
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA200900691A1 publication Critical patent/EA200900691A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описаны способы лечения гематологических злокачественных заболеваний, включая острый миелоидный лейкоз (AML), заключающиеся в том, что применяют соединения, которые ингибируют связывание белка Smac с IAP («ингибитор IAP»). В заявке описано также применение ингибиторов IAP для приготовления лекарственного средства, предназначенного для лечения гематологических злокачественных заболеваний, включая AML.
EA200900691A 2006-11-28 2007-11-26 Применение ингибиторов iap для лечения острого миелоидного лейкоза EA200900691A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86745006P 2006-11-28 2006-11-28
PCT/US2007/085486 WO2008085610A1 (en) 2006-11-28 2007-11-26 Use of iap inhibitors for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
EA200900691A1 true EA200900691A1 (ru) 2009-12-30

Family

ID=39342685

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900691A EA200900691A1 (ru) 2006-11-28 2007-11-26 Применение ингибиторов iap для лечения острого миелоидного лейкоза

Country Status (11)

Country Link
US (1) US20100076013A1 (ru)
EP (1) EP2089027A1 (ru)
JP (1) JP2010511057A (ru)
KR (1) KR20090083412A (ru)
CN (1) CN101541325A (ru)
AU (1) AU2007342225A1 (ru)
BR (1) BRPI0719559A2 (ru)
CA (1) CA2670270A1 (ru)
EA (1) EA200900691A1 (ru)
MX (1) MX2009005551A (ru)
WO (1) WO2008085610A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
KR20080067357A (ko) 2005-10-25 2008-07-18 에게라 쎄라퓨틱스 인코포레이티드 Ｉａｐ ｂｉｒ 도메인 결합 화합물
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
JP2013505446A (ja) * 2009-09-18 2013-02-14 ノバルティス アーゲー Ｉａｐ阻害剤化合物のためのバイオマーカー
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238650A1 (en) * 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
KR20080083220A (ko) * 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
ES2684120T3 (es) * 2005-12-20 2018-10-01 Novartis Ag Combinación de un inhibidor de IAP y un taxano
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
MX2009005551A (es) 2009-06-08
BRPI0719559A2 (pt) 2014-01-21
US20100076013A1 (en) 2010-03-25
EP2089027A1 (en) 2009-08-19
AU2007342225A1 (en) 2008-07-17
CN101541325A (zh) 2009-09-23
WO2008085610A1 (en) 2008-07-17
KR20090083412A (ko) 2009-08-03
CA2670270A1 (en) 2008-07-17
JP2010511057A (ja) 2010-04-08

Similar Documents

Publication Publication Date Title
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA200900227A1 (ru) Пептидомиметики smac, применимые в качестве ингибиторов iap (ингибитор белков апоптоза)
TW200738725A (en) Unsaturated mTOR inhibitors
MY147832A (en) Compounds for enzyme inhibition
SG179418A1 (en) Inhibitors of the hedgehog pathway
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
GT201100181A (es) "inhibidores de proteina cinasa"
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
WO2009156735A3 (en) New therapeutic agents
GEP20125511B (en) Mapk/erk kinase inhibitors
DK2099461T3 (da) LNA Nukleoside Phosphoramidates
MY148651A (en) Antitumoral compounds
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi
EA201070295A1 (ru) Лечение рака легких
MD3358G2 (ru) 12-Гидроперокси-8а, 12-эпокси-11-бисгомодриман для использования при лечении грибковых заболеваний
CY1116810T1 (el) Πολυνουκλεοτιδια αντι-κοννεξινης ως συνθεσεις διαταραγμενης επουλωσης πληγων
UA100869C2 (ru) Лечение рака яичника с помощью соединения йодонитробензамида в комбинации с противоопухолевыми средствами